The non-thiol angiotensin-converting enzyme inhibitor quinapril suppresses inflammatory arthritis

Rheumatology

Volumn 44, Issue 1, 2005, Pages 24-31

  Dalbeth, N ^a,b   Edwards, J ^c   Fairchild, S ^d   Callan, M ^a,b   Hall, F C ^b,d  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Angiotensin II; Inflammation; Monocytes macrophages; Rheumatoid arthritis

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; AUTACOID; CANDESARTAN HEXETIL; CAPTOPRIL; COLLAGEN TYPE 2; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOGLOBULIN G; LIPOPOLYSACCHARIDE; QUINAPRIL; QUINAPRILAT; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ARTHRITIS, EXPERIMENTAL; COLLAGEN TYPE II; CYTOKINES; EPITOPES; IMMUNOGLOBULIN G; MALE; MICE; MICE, INBRED DBA; MONOCYTES; PEPTIDYL-DIPEPTIDASE A; TETRAHYDROISOQUINOLINES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 12344308309     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keh398     Document Type: Article

References (53)

1. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987;316:1429-35.
2. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8.
3. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.
4. Ruggenenti P, Perna A, Gherardi G et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999;354:359-64.
5. Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J. Inflammation and angiotensin II. Int J Biochem Cell Biol 2003;35:881-900.
6. Kitazono T, Padgett RC, Armstrong ML, Tompkins PK, Heistad DD. Evidence that angiotensin II is present in human monocytes. Circulation 1995;91:1129-34.
7. Okamura A, Rakugi H, Ohishi M et al. Upregulation of renin-angiotensin system during differentiation of monocytes to macrophages. J Hypertens 1999;17:537-45.
8. Nahmod KA, Vermeulen ME, Raiden S et al. Control of dendritic cell differentiation by angiotensin II. Faseb J 2003;17:491-3.
9. Kranzhofer R, Browatzki M, Schmidt J, Kubler W. Angiotensin II activates the proinflammatory transcription factor nuclear factor-kappaB in human monocytes. Biochem Biophys Res Commun 1999;257:826-8.
10. Ruiz-Ortega M, Bustos C, Hernandez-Presa MA, Lorenzo O, Plaza JJ, Egido J. Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 synthesis. J Immunol 1998;161:430-9.
11. Tham DM, Martin-McNulty B, Wang YX et al. Angiotensin II is associated with activation of NF-kappaB-mediated genes and down-regulation of PPARs. Physiol Genomics 2002;11:21-30.
12. Hernandez-Presa M, Bustos C, Ortego M et al. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 1997;95:1532-41.
13. Fukuzawa M, Satoh J, Sagara M et al. Angiotensin converting enzyme inhibitors suppress production of tumor necrosis factor-alpha in vitro and in vivo. Immunopharmacology 1997;36:49-55.
14. Lapteva N, Ide K, Nieda M et al. Activation and suppression of renin-angiotensin system in human dendritic cells. Biochem Biophys Res Commun 2002;296:194-200.
15. Marok R, Winyard PG, Coumbe A et al. Activation of the transcription factor nuclear factor-kappaB in human inflamed synovial tissue. Arthritis Rheum 1996;39:583-91.
16. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.
17. Goto M, Fujisawa M, Yamada A et al. Spontaneous release of angiotensin converting enzyme and interleukin 1 beta from peripheral blood monocytes from patients with rheumatoid arthritis under a serum free condition. Ann Rheum Dis 1990;49:172-6.
18. Goto M, Sasano M, Fuzisawa M, Okabe T, Nishizawa K. Constitutive production of angiotensin converting enzyme from rheumatoid nodule cells under serum free conditions. Ann Rheum Dis 1992;51:741-2.
19. Veale D, Yanni G, Bresnihan B, FitzGerald O. Production of angiotensin converting enzyme by rheumatoid synovial membrane. Ann Rheum Dis 1992;51:476-80.
20. Walsh DA, Catravas J, Wharton J. Angiotensin converting enzyme in human synovium: increased stromal [(125)I]351A binding in rheumatoid arthritis. Ann Rheum Dis 2000;59:125-31.
21. Walsh DA, Suzuki T, Knock GA, Blake DR, Polak JM, Wharton J. AT1 receptor characteristics of angiotensin analogue binding in human synovium. Br J Pharmacol 1994;112:435-42.
22. Martin MF, Surrall KE, McKenna F, Dixon JS, Bird HA, Wright V. Captopril: a new treatment for rheumatoid arthritis? Lancet 1984;1:1325-8.
23. Bird HA, Le Gallez P, Dixon JS et al. A clinical and biochemical assessment of a nonthiol ACE inhibitor (pentopril; CGS-13945) in active rheumatoid arthritis. J Rheumatol 1990;17:603-8.
24. Rosloniec EF, Kang AH, Myers LK, Cremer MA. Collagen-Induced Arthritis. New York, NY: Wiley & Sons, 1997.
25. Wolfenson S, Lloyd M. Handbook of laboratory animal management and welfare. 2nd edn. Oxford, UK: Blackwell Science, 1998.
26. Dzau VJ, Bernstein K, Celermajer D et al. The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol 2001;88:1L-20L.
27. Sawada T, Ishii Y, Tojimbara T, Nakajima I, Fuchinoue S, Teraoka S. The ACE inhibitor, quinapril, ameliorates peritoneal fibrosis in an encapsulating peritoneal sclerosis model in mice. Pharmacol Res 2002;46:505-10.
28. Suzuki Y, Lopez-Franco O, Gomez-Garre D et al. Renal tubulointerstitial damage caused by persistent proteinuria is attenuated in AT1-deficient mice: role of endothelin-1. Am J Pathol 2001;159:1895-904.
29. MacDonald JR, Susick RL Jr, Pegg DG, Dominick MA. Renal structure and function in rats after suprapharmacologic doses of quinapril, an angiotensin-converting enzyme inhibitor. J Cardiovasc Pharmacol 1992;19:282-9.
30. Mori T, Nishimura H, Okabe M, Ueyama M, Kubota J, Kawamura K. Cardioprotective effects of quinapril after myocardial infarction in hypertensive rats. Eur J Pharmacol 1998;348:229-34.
31. Holmquist B, Bunning P, Riordan JF. A continuous spectrophotometric assay for angiotensin converting enzyme. Anal Biochem 1979;95:540-8.
32. Altman DG. Practical statistics for medical research. Boca Raton, FL, USA: Chapman and Hall, 1991.
33. Agha AM, Mansour M. Effects of captopril on interleukin-6, leukotriene B(4), and oxidative stress markers in serum and inflammatory exudate of arthritic rats: evidence of antiinflammatory activity. Toxicol Appl Pharmacol 2000;168:123-30.
34. Caspritz G, Alpermann HG, Schleyerbach R. Influence of the new angiotensin converting enzyme inhibitor ramipril on several models of acute inflammation and the adjuvant arthritis in the rat. Arzneimittelforschung 1986;36:1605-8.
35. McCarey DW, McInnes IB, Madhok R et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004;363:2015-21.
36. Schellens JH, Malingre MM, Kruijtzer CM et al. Modulation of oral bioavailability of anticancer drugs: from mouse to man. Eur J Pharm Sci 2000;12:103-10.
37. Waeber B, Nussberger J, Juillerat L, Brunner HR. Angiotensin converting enzyme inhibition: discrepancy between antihypertensive effect and suppression of enzyme activity. J Cardiovasc Pharmacol 1989;14(Suppl. 4):S53-9.
38. Nash DT. Comparative properties of angiotensin-converting enzyme inhibitors: relations with inhibition of tissue angiotensin-converting enzyme and potential clinical implications. Am J Cardiol 1992; 69:26C-32C.
39. Godsel LM, Leon JS, Wang K, Fornek JL, Molteni A, Engman DM. Captopril prevents experimental autoimmune myocarditis. J Immunol 2003;171:346-52.
40. Kuno A, Yamada T, Masuda K et al. Angiotensin-converting enzyme inhibitor attenuates pancreatic inflammation and fibrosis in male Wistar Bonn/Kobori rats. Gastroenterology 2003;124:1010-9.
41. Constantinescu CS, Ventura E, Hilliard B, Rostami A. Effects of the angiotensin converting enzyme inhibitor captopril on experimental autoimmune encephalomyelitis. Immunopharmacol Immunotoxicol 1995;17:471-91.
42. Boom WH, Liano D, Abbas AK. Heterogeneity of helper/inducer T lymphocytes. II. Effects of interleukin 4- and interleukin 2-producing T cell clones on resting B lymphocytes. J Exp Med 1988;167:1350-63.
43. Stuart JM, Cremer MA, Townes AS, Kang AH. Type II collagen-induced arthritis in rats. Passive transfer with serum and evidence that IgG anticollagen antibodies can cause arthritis. J Exp Med 1982;155:1-16.
44. Svensson L, Jirholt J, Holmdahl R, Jansson L. B cell-deficient mice do not develop type II collagen-induced arthritis (CIA). Clin Exp Immunol 1998;111:521-6.
45. Boissier MC, Carlioz A, Fournier C. Experimental autoimmune arthritis in mice. II. Early events in the elicitation of the autoimmune phenomenon induced by homologous type II collagen. Clin Immunol Immunopathol 1988;48:225-37.
46. Solomon DH, Karlson EW, Rimm EB et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003;107:1303-7.
47. del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737-45.
48. Myllykangas-Luosujarvi R, Aho K, Kautiainen H, Isomaki H. Cardiovascular mortality in women with rheumatoid arthritis. J Rheumatol 1995;22:1065-7.
49. Bacon PA, Townend JN. Nails in the coffin: increasing evidence for the role of rheumatic disease in the cardiovascular mortality of rheumatoid arthritis. Arthritis Rheum 2001;44:2707-10.
50. Del Rincon I, Williams K, Stern MP, Freeman GL, O'Leary DH, Escalante A. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 2003;48:1833-40.
51. Youssef S, Stuve O, Patarroyo JC et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002;420: 78-84.
52. Leung BP, Sattar N, Crilly A et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 2003;170:1524-30.
53. Oubina MP, De Las Heras N, Cediel E et al. The synergic effect of ACE and HMG-CoA reductase inhibition on inflammatory markers in atherosclerotic rabbits. Clin Sci (Lond) 2003;105:655-62.